

FDA warns against long-term azithromycin use for some

August 13 2018



(HealthDay)—The U.S. Food and Drug Administration is warning

patients with cancers of the blood or lymph nodes who undergo a donor stem cell transplant not to take azithromycin, as long-term use of the antibiotic has been associated with increased risk of cancer relapse.

In a clinical trial, azithromycin was being used to prevent bronchiolitis obliterans syndrome in patients with cancers of the blood or lymph nodes who underwent a donor stem cell transplant. However, long-term use of the antibiotic was tied to cancer relapse and death.

"Health care professionals should not prescribe long-term azithromycin for prophylaxis of bronchiolitis obliterans syndrome to patients who undergo donor [stem cell transplants](#) because of the increased potential for [cancer relapse](#) and death," the agency said in a statement.

Health care professionals and patients are encouraged to report adverse events or side effects related to the use of azithromycin to the FDA's MedWatch Safety Information and Adverse Event Reporting Program.

More information: [More Information](#)
[MedWatch Reporting](#)

Copyright © 2018 [HealthDay](#). All rights reserved.

Citation: FDA warns against long-term azithromycin use for some (2018, August 13) retrieved 27 April 2024 from <https://medicalxpress.com/news/2018-08-fda-long-term-azithromycin.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
